Is birtamimab an option for patients with advanced AL amyloidosis at high risk for early death?

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition , the Multiple Myeloma Hub was pleased to speak to Morie Gertz, Mayo Clinic, Rochester, US. We asked, Is birtamimab an option for patients with advanced amyloid light-chain (AL) amyloidosis at high risk for early death?

Gertz opens by discussing the current treatment options available for patients with AL amyloidosis, noting that they are primarily preventative and there is a lack of treatment options for existing amyloid deposits; limiting options for patients who receive a late diagnosis. Gertz goes on to discuss birtamimab as an amyloid depleting antibody that has the potential to be effective at targeting existing amyloid deposits.

Gertz concludes by discussing that the post hoc analysis from a study terminated back in April 2018 has led to the initiation of a phase III trial (AFFIRM-AL, NCT04973137), currently recruiting treatment-naive patients with Stage IV cardiac AL amyloidosis.